Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension

William Wilson Kemp, Henry Krum, John Colman, Michael John Bailey, Tim Yandle, Mark Richards, Stuart Roberts

Research output: Contribution to journalArticleResearchpeer-review

28 Citations (Scopus)


BACKGROUND/AIMS: Urotensin II (UII) is recognised as the most potent human vasoconstrictor; however, its role in chronic liver disease (CLD) is unknown. AIM: We sought to determine serum UII levels in CLD and explore its relationship with clinical features and outcomes of patients with CLD and portal hypertension. METHODS: UII was analysed by radio-immunoassay on cirrhotic patients undergoing hepatic venous pressure gradient (HVPG) determination and age- and sex-matched controls. Follow-up data were prospectively recorded. RESULTS: From 1997 to 2004, 80 patients (male/female: 74/6) underwent a total of 94 HVPG assessments. UII was higher in cirrhotic patients compared with controls (2.05+/-0.06 and 1.55+/-0.09 pmol/L, P
Original languageEnglish
Pages (from-to)1232 - 1239
Number of pages8
JournalLiver International
Issue number9
Publication statusPublished - 2007

Cite this